GOLDMAN SACHS GROUP INC (GS) Stock News

IGSB and SMB are both short-duration bond ETFs serving different investor needs. IGSB focuses on investment-grade corporate bonds with higher yield (4.7%) and better 5-year returns (14%), while SMB targets tax-exempt municipal bonds with tax advantages. IGSB has lower costs (0.04% expense ratio) and larger assets under management ($23.5B), making it attractive for income-focused investors, whereas SMB appeals to those seeking tax efficiency.

Rosen Law Firm announces a securities class action lawsuit against Hyliion Holdings Corp., alleging the company made false and misleading statements regarding its VFG Holdings partnership and commercial pipeline credibility. Investors who purchased HYLN stock between May 12, 2026 and June 23, 2026 may be eligible for compensation. The lead plaintiff deadline is October 27, 2026.

Rosen Law Firm has filed securities class action lawsuits against Innventure, Inc., Flotek Industries, Inc., and Hims & Hers Health, Inc., alleging materially false and misleading statements. Innventure is accused of overstating revenue targets related to Accelsius Holdings' deal with DarkNX. Investors have until specified deadlines in late October and early November 2026 to join the class actions.

Great Southern Bancorp (GSBC) reported Q3 2026 earnings of $1.50 per share, beating consensus estimates of $1.39, with a 7.91% earnings surprise. Revenue of $57.74 million also exceeded expectations by 3.85%. However, the stock received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market. The company's industry (Financial - Savings and Loan) ranks in the bottom 29% of Zacks industries.

Rosen Law Firm has filed securities class action lawsuits against multiple companies. Honeywell Aerospace Inc. faces allegations of making false statements regarding supplier concentration risks, supply constraints, and undisclosed government contract investigations. York Space Systems Inc. and Webull Corporation also have pending class actions. Investors are urged to secure counsel before respective deadlines.

GSK is expected to report a year-over-year earnings decline of 5.4% to $1.40 per share for Q3 2026, despite revenues rising 2.4% to $11.8 billion. With a negative Earnings ESP of -4.56% and Zacks Rank #4, the stock is not considered a compelling earnings-beat candidate. The company has historically beaten estimates in recent quarters, but recent analyst revisions suggest bearish sentiment on near-term earnings prospects.

HUTCHMED has completed an exclusive development and license agreement with GSK subsidiary, granting GSK worldwide rights (excluding Greater China and Taiwan) to develop and commercialize HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate. HUTCHMED will receive $110 million upfront and up to $1.185 billion in milestone payments, plus tiered royalties. HUTCHMED remains responsible for global Phase I development.

Rosen Law Firm reminds investors who purchased XTI Aerospace securities between April 15, 2026 and August 17, 2026 of the October 27, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that senior executives engaged in undisclosed activities, raising doubts about disclosure controls and the company's ability to file timely earnings reports, making positive statements about the business materially misleading.

Rosen Law Firm has filed securities class action lawsuits against AppLovin Corporation, Lincoln Educational Services Corporation, and Beta Bionics, Inc. The AppLovin lawsuit alleges the company made false statements regarding AI video creative features and overstated the benefits of its AI models. Investors who purchased securities during specified class periods are encouraged to seek counsel before upcoming lead plaintiff deadlines.

PagSeguro Digital Ltd. (PAGS) closed at $11.12, up 2.68%, outperforming the S&P 500's 0.33% gain. The stock has gained 14.36% prior to today's trading. Analysts expect Q3 earnings of $0.41 per share (13.89% YoY growth) and revenue of $996.2 million (6.3% growth). For the full year, consensus estimates project $1.65 EPS and $4.02 billion revenue, representing 16.2% and 10.02% growth respectively. PAGS carries a Zacks Rank #3 (Hold) with a Forward P/E of 6.56, trading at a discount to its industry average of 14.32.

Saudi Arabia's Non-Invasive Prenatal Testing (NIPT) market is projected to grow from US$52.50 million in 2025 to US$162.16 million by 2034, driven by a 13.35% CAGR. Growth is fueled by advances in next-generation sequencing, rising maternal age, increased healthcare investment, and expanding genetic testing capacity. Key players include Eurofins Scientific, Roche, Invitae, Illumina, Natera, Centogene, and Qiagen, with Riyadh and Jeddah leading regional adoption.

Rosen Law Firm has filed a class action lawsuit against Millrose Properties, Inc. (NYSE: MRP) on behalf of investors who purchased securities between February 7, 2025 and October 2, 2026. The lawsuit alleges that defendants failed to disclose that Millrose's business operations diverged from stated objectives, including entering into lease agreements at a loss and purchasing $200 million in properties from Lennar Corporation. The firm is seeking lead plaintiffs with a deadline of December 8, 2026.

Figs Inc., a healthcare apparel company, demonstrates strong momentum characteristics with a Zacks Momentum Style Score of B and a Zacks Rank #2 (Buy) rating. The stock has surged 16.72% over the past week and 150.21% over the past year, significantly outperforming the S&P 500. Recent earnings estimate revisions have been positive, with consensus estimates increasing from $0.32 to $0.36 in the past 60 days, supporting the bullish outlook.

The complicated urinary tract infections (cUTI) market is expected to grow steadily through 2036, driven by rising antimicrobial resistance, increasing recurrent and hospital-acquired infections, and recent drug approvals. Key approvals include GSK/Spero Therapeutics' UTEBZI (oral antibiotic) and Wockhardt's ZAYNICH (intravenous antibiotic), both approved in 2026. Emerging therapies from companies like Venatorx Pharmaceuticals, Meiji Seika Pharma, and Locus Biosciences targeting multidrug-resistant Gram-negative bacteria are expected to further expand the market.

The article compares two Vanguard short-term bond ETFs: VGSH (Treasury ETF) and VCSH (Corporate Bond ETF). Both charge 0.03% expense ratios, but VCSH offers higher yield (4.56%) with more volatility, while VGSH provides lower risk with 3.78% yield. The author recommends VGSH for current economic conditions due to recession concerns and elevated interest rates, suggesting VCSH is better suited for purchasing during economic downturns.

Figs (FIGS) shares rose 6.5% to $14.98 on strong volume, supported by positive earnings expectations of $0.07 per share (+40% YoY) and revenue growth of 19.5%. The company benefits from strong customer engagement, product innovation, and expanding international operations. Earnings estimate revisions have been revised 1.2% higher over the past month, suggesting continued momentum. The stock carries a Zacks Rank #2 (Buy) rating.

Rosen Law Firm has filed class action lawsuits on behalf of investors in Celsius Holdings, Inc. and other companies. The Celsius lawsuit alleges that the company made materially false and misleading statements regarding cardiac risks associated with Alani Nu products and inappropriately marketed these products to consumers under 18. Investors who purchased securities during the specified class periods may be eligible for compensation. The deadline to serve as lead plaintiff is November 3, 2026.

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against Papa John's International (PZZA) on behalf of investors who purchased stock between August 7, 2025 and August 5, 2026. The lawsuit alleges that Papa John's made materially false and misleading statements about its transformation efforts, which were taking longer than expected and failed to prevent market share losses, requiring a shift toward increased promotional efforts.

PagSeguro Digital Ltd. (PAGS) declined 2.1% to $10.72 on October 6, 2026, underperforming broader market gains. Despite a 12.54% monthly gain, the stock faces headwinds with a slight 1.05% downward revision in consensus EPS estimates over the past month. The company holds a Zacks Rank #3 (Hold) rating, though it trades at a discount valuation with a Forward P/E of 6.64 versus the industry average of 14.59.

PagSeguro Digital shares jumped 21.4% to $10.95 on strong volume, driven by its integrated fintech platform and positive sentiment from Brazil's presidential election outcome. However, earnings estimate revisions have declined 4.3% over the past 30 days, suggesting caution about sustained momentum. The company carries a Zacks Rank #3 (Hold) rating.

Goldman Sachs is expected to report Q3 2026 earnings on October 13 with consensus estimates of $13.89 EPS (up 13.4% YoY) and $16.91B in revenues (up 11.4% YoY). However, recent analyst revisions have turned bearish, resulting in a negative Earnings ESP of -11.16%, making an earnings beat unlikely despite the stock's Zacks Rank #3 rating. The company has a strong history of beating estimates, having exceeded consensus four consecutive quarters.

Zacks Equity Research analysts featured four retail stocks in their blog. Victoria's Secret remains confident in China as its top international growth driver despite moderating international growth. FIGS, Fossil Group, and Boot Barn are highlighted as better-ranked alternatives with varying growth prospects in their respective sectors.

Zacks.com released analyst research reports on five stocks on October 6, 2026. Texas Instruments and Marvell Technology showed strong outperformance driven by demand in industrial, data center, and AI sectors. RTX benefited from aerospace recovery and defense demand. Air T showed improvement in aviation services, while GSI Technology faced headwinds in commercialization despite potential in AI processing applications.

Rosen Law Firm has filed securities class action lawsuits against Taboola.com Ltd., The Simply Good Foods Company, and Tigo Energy, Inc. The firm is seeking lead plaintiffs and encouraging investors who purchased securities during specified class periods to join the litigation. The lawsuits allege materially false and misleading statements regarding business operations and financial prospects.

The global immunogenomics market is projected to grow from USD 6.32 billion in 2025 to USD 9.82 billion by 2033, expanding at a CAGR of 5.97%. Growth is driven by advancements in next-generation sequencing technologies, increasing demand for personalized medicine, and rising prevalence of immune-related disorders. Key applications include oncology, infectious disease research, vaccine development, and autoimmune disorder studies, with adoption across hospitals, diagnostic laboratories, pharmaceutical companies, and academic institutions.

Rosen Law Firm is reminding investors in Blaize Holdings, Smartsheet Inc., and DICK'S Sporting Goods of upcoming lead plaintiff deadlines in securities class actions. The lawsuits allege false statements, improper revenue recognition, and undisclosed business practices that caused investor damages.

A class action lawsuit has been filed against Blaize Holdings, Inc. (NASDAQ: BZAI) for allegedly making false and misleading statements regarding revenue recognition and announcing transactions with unequipped entities to create an appearance of growth. Investors who purchased Blaize securities between July 17, 2025 and August 13, 2026 have until October 5, 2026 to apply as lead plaintiff.

Goldman Sachs has been a trending stock with shares down 8.6% over the past month. The company is expected to report strong earnings growth of 35.7% for the current fiscal year with revenue growth of 22.9%. Goldman recently beat consensus estimates with a 44.99% EPS surprise and 23.31% revenue surprise. However, the stock carries a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term, and is valued at par with its peers.

Trio Petroleum Corp acquired 24 oil wells (4 producing, 20 shut-in) from Marlin Resources Ltd in Saskatchewan's Lloydminster region for CDN$800,000 cash plus an underutilized water disposal asset. The acquisition includes 37 BOPD of current production, a planned Cummings multilateral well with CDN$1.2 million development budget, and a CDN$425,000 workover program. The company expects the purchase price per flowing barrel to be discounted compared to market rates for comparable assets.

A class action lawsuit has been filed against Blaize Holdings, Inc. (NASDAQ: BZAI) for allegedly making false and misleading statements regarding revenue recognition and announcing transactions with unequipped entities to create an appearance of growth. Investors who purchased Blaize securities between July 17, 2025 and August 13, 2026 have until October 5, 2026 to apply as lead plaintiff.